AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27832514 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973
Number of subjects: 0
Study 25890060 — intervention group
Group type: EXPERIMENTAL
Intervention: Action group (children created an action implementation intention)
Number of subjects: 400
Study 25890060 — intervention group
Group type: COMPARATOR
Intervention: Control groups (none, coping, both)
Number of subjects: 400
Study 23053709 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer technique, consisting of a first layer of GIC with a flowable consistency (powder/liquid ratio 1:2) and a second layer of a regular consistency
Number of subjects: 208
Study 23053709 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique, one-layer GIC (powder/liquid ratio 1:1)
Number of subjects: 208
Study 21226681 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR of 0.80 or greater with a BMI of 20.0 to 24.9 kg/m²
Number of subjects: 7163
Study 21226681 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR less than 0.80 and a BMI of 20.0 to 24.9 kg/m²
Number of subjects: 7163
Study 21226681 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight women (BMI < 20.0 kg/m²) with a WHR less than 0.80
Number of subjects: 7163
Study 21226681 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight to obese women (BMI 20.0-29.9 kg/m²) with central adiposity (WHR ≥ 0.80)
Number of subjects: 7163
Study 17868404 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospo-soda buffered saline (Fleet)
Number of subjects: 73
Study 17868404 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulphate/magnesium citrate (Picoprep)
Number of subjects: 73
Study 16857842 — intervention group
Group type: EXPERIMENTAL
Intervention: High Botanical Diversity Diet (HBD)
Number of subjects: 106
Study 16857842 — intervention group
Group type: COMPARATOR
Intervention: Low Botanical Diversity Diet (LBD)
Number of subjects: 106
Study 15043519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral branched chain amino acids
Number of subjects: 84
Study 15043519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplement)
Number of subjects: 84
Study 11764826 — intervention group
Group type: EXPERIMENTAL
Intervention: MD15 Oral Irrigator plus manual brushing
Number of subjects: 64
Study 11764826 — intervention group
Group type: COMPARATOR
Intervention: Manual brushing alone
Number of subjects: 64
Study 9493701 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 10 mg
Number of subjects: 190
Study 9493701 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 20 mg
Number of subjects: 190
Study 9493701 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnidipine 30 mg
Number of subjects: 190
Study 9493701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 8227108 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression sclerotherapy (CST; n = 78)
Number of subjects: 211
Study 8227108 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical operation (OP; n = 74)
Number of subjects: 211
Study 8227108 — intervention group
Group type: EXPERIMENTAL
Intervention: CST combined with high tie under local anesthesia (HT + CST; n = 63)
Number of subjects: 211
Study 8227108 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot-volumetric parameters (all groups)
Number of subjects: 211
Study 3947505 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg diclofenac sodium
Number of subjects: 48
Study 3947505 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg diclofenac sodium
Number of subjects: 48
Study 3947505 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 48
Study 3947505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30392496 — intervention group
Group type: EXPERIMENTAL
Intervention: PsP 750mg/day in 3 divided doses for 90 days
Number of subjects: 71
Study 27906080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic stimulation for 12 weeks
Number of subjects: 0
Study 27906080 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst stimulation for 12 weeks
Number of subjects: 0
Study 27906080 — intervention group
Group type: COMPARATOR
Intervention: Tonic stimulation
Number of subjects: 0
Study 27906080 — intervention group
Group type: COMPARATOR
Intervention: Burst stimulation
Number of subjects: 0
Study 25335686 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk enriched with sterols (2.24 g per day)
Number of subjects: 19
Study 25335686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (skim milk)
Number of subjects: 19
Study 22417253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral laquinimod 0.6 mg once daily
Number of subjects: 1106
Study 22417253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study 20709206 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (intervention)
Number of subjects: 0
Study 20709206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20709206 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 0
Study 19084097 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0
Study 19084097 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 0
Study 15657221 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (Bruce protocol)
Number of subjects: 26
Study 12604533 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 25 mg/kg/dose b.i.d.
Number of subjects: 66
Study 12604533 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 15 mg/kg/dose t.i.d.
Number of subjects: 66
Study 10390311 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of wrist extensors (3 times 30 minutes daily for 8 weeks)
Number of subjects: 60
Study 10390311 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of wrist extensors
Number of subjects: 60
Study 10390311 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation treatment
Number of subjects: 60
Study 8894861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinised lignocaine
Number of subjects: 98
Study 8894861 — intervention group
Group type: COMPARATOR
Intervention: Non-alkalinised lignocaine
Number of subjects: 98
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to isocyanates
Number of subjects: 69
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to IgE sensitizing agents
Number of subjects: 69
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to western red cedar
Number of subjects: 69
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical patterns of reactions
Number of subjects: 69
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical reactions
Number of subjects: 69
Study 2005315 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment vs polynomial fit analysis
Number of subjects: 69
Study 6650801 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg kg‐1 i.v.
Number of subjects: 40
Study 6650801 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg kg‐1 i.v.
Number of subjects: 40
Study 30941435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ME levels of 2,600; 2,700; 2,800; 2,900; and 3,000 kcal/kg of feed
Number of subjects: 640
Study 30941435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beak trimming once (7 days old)
Number of subjects: 640
Study 30941435 — intervention group
Group type: COMPARATOR
Intervention: Beak trimming twice (7 and 70 days old)
Number of subjects: 640
Study 30941435 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ME levels
Number of subjects: 640
Study 30941435 — intervention group
Group type: EXPERIMENTAL
Intervention: Beak trimming once
Number of subjects: 640
Study 30941435 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dietary ME levels and beak trimming hens once
Number of subjects: 640
Study 30001765 — intervention group
Group type: EXPERIMENTAL
Intervention: UAV technology
Number of subjects: 40
Study 30001765 — intervention group
Group type: COMPARATOR
Intervention: Standard Practice (SP)
Number of subjects: 40
Study 26668200 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 258
Study 26668200 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 258
Study 25129531 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Bipolar (LWB) intervention
Number of subjects: 122
Study 25129531 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 122
Study 22055112 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLF-CB (cetuximab 400 mg/m2 day 1 cycle 1; subsequent doses 250 mg/m2 weekly, along with bevacizumab, leucovorin, and 5-FU)
Number of subjects: 247
Study 22055112 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6-B (bevacizumab 5 mg/kg, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and 5-FU 400 mg/m2 then 1200 mg/m2/day for 48 hours)
Number of subjects: 247
Study 22055112 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLF-CB
Number of subjects: 247
Study 22055112 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6-B
Number of subjects: 247
Study 19182972 — intervention group
Group type: COMPARATOR
Intervention: 2% NaF
Number of subjects: 50
Study 19182972 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser (1 W, continuous wave mode, for 10 sec)
Number of subjects: 50
Study 19182972 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (30 Hz, 60 mJ for 10 sec, without water/air spray)
Number of subjects: 50
Study 19182972 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) + 2% NaF
Number of subjects: 50
Study 19182972 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG + 2% NaF
Number of subjects: 50
Study 17452287 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (30mg)
Number of subjects: 13
Study 17452287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16055645 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in Oriental medicine
Number of subjects: 0
Study 16055645 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of training in Oriental medicine
Number of subjects: 0
Study 12418051 — intervention group
Group type: EXPERIMENTAL
Intervention: FOBT and endoscopy with polypectomy
Number of subjects: 0
Study 12418051 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic tests and imaging studies
Number of subjects: 0
Study 9431330 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-managed residential care (CMRC)
Number of subjects: 358
Study 9431330 — intervention group
Group type: COMPARATOR
Intervention: 21-day hospital program with referral to community services
Number of subjects: 358
Study 7730879 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Symptom Index (12 symptoms: fatigue, fevers, headache, imbalance, paresthesias, memory loss, cough, nausea, diarrhea, sadness, sleep disturbance, skin problems)
Number of subjects: 148
Study 2660550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension 1 g/10 ml four times per day
Number of subjects: 292
Study 2660550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 2660550 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking (regardless of treatment group)
Number of subjects: 292
Study 30813112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Number of subjects: 1350
Study 30813112 — intervention group
Group type: COMPARATOR
Intervention: Specialty outpatient palliative care
Number of subjects: 1350
Study 28389582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158
Study 28389582 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 158
Study 28389582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) Satisfaction Survey
Number of subjects: 158
Study 26417132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal packing (Group A)
Number of subjects: 40
Study 26417132 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal packing (Group B)
Number of subjects: 40
Study 23143698 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball shoes (BS)
Number of subjects: 12
Study 20724681 — intervention group
Group type: EXPERIMENTAL
Intervention: Active water treatment units
Number of subjects: 769
Study 20724681 — intervention group
Group type: COMPARATOR
Intervention: Sham water treatment units
Number of subjects: 769
Study 19485582 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power‐training plus feedback (CP‐TF)
Number of subjects: 57
Study 19485582 — intervention group
Group type: COMPARATOR
Intervention: Coping Power‐basic training (CP‐BT)
Number of subjects: 57
Study 19485582 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 57
Study 16485765 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal QRST cancellation (STC)
Number of subjects: 30
Study 16485765 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA)
Number of subjects: 30
Study 16485765 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent component analysis (ICA)
Number of subjects: 30
Study 15561950 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD antibody positive patients
Number of subjects: 4134
Study 15561950 — intervention group
Group type: COMPARATOR
Intervention: GAD antibody negative patients
Number of subjects: 4134
Study 11772575 — intervention group
Group type: COMPARATOR
Intervention: high-O(2) soft lens (6-night EW)
Number of subjects: 178
Study 11772575 — intervention group
Group type: EXPERIMENTAL
Intervention: hyper-O(2) soft lens (30-night EW)
Number of subjects: 178
Study 11772575 — intervention group
Group type: EXPERIMENTAL
Intervention: hyper-O(2) rigid gas-permeable lens (30-night EW)
Number of subjects: 178
Study 9530380 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 50
Study 9530380 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenosis
Number of subjects: 50
Study 9530380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IMT
Number of subjects: 50
Study 7912478 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 6
Study 7912478 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 6
Study 7912478 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxacurium
Number of subjects: 6
Study 2917399 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti-Free chemical disinfectant under exaggerated conditions (Group A)
Number of subjects: 51
Study 2917399 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti-Free chemical disinfectant under normal daily use (Group A)
Number of subjects: 51
Study 2917399 — intervention group
Group type: COMPARATOR
Intervention: Normal daily use regimen (Group B)
Number of subjects: 51
Study 30273819 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched amino acid supplement
Number of subjects: 44
Study 30273819 — intervention group
Group type: COMPARATOR
Intervention: Control (no leucine-enriched amino acid supplement)
Number of subjects: 44
Study 28545580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) after 5 therapy-preparing sessions
Number of subjects: 48
Study 26325427 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ceramic hydroxyapatite (ncHA)
Number of subjects: 11
Study 26325427 — intervention group
Group type: COMPARATOR
Intervention: Intra-oral autologous bone graft
Number of subjects: 11
Study 26325427 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ncHA and autologous bone)
Number of subjects: 11
Study 26325427 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant stability quotient (ISQ)
Number of subjects: 11
Study 23871112 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted phacoemulsification
Number of subjects: 2
Study 23871112 — intervention group
Group type: COMPARATOR
Intervention: Standard phacoemulsification (control group)
Number of subjects: 2
Study 22616337 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (messages sent once every 3 days for 1 year)
Number of subjects: 215
Study 22616337 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 215
Study 19624628 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Number of subjects: 60
Study 19624628 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Number of subjects: 60
Study 17081212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker implantation
Number of subjects: 262
Study 17081212 — intervention group
Group type: COMPARATOR
Intervention: Cumulative right ventricular pacing ≥ 50%
Number of subjects: 262
Study 15112033 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Care Outreach service
Number of subjects: 7450
Study 15112033 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7450
Study 11706909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 237
Study 11706909 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (600 mg) with codeine (60 mg) and caffeine (15 mg) (Tylenol No. 3)
Number of subjects: 237
Study 17008969 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic decompression (group B)
Number of subjects: 120
Study 17008969 — intervention group
Group type: COMPARATOR
Intervention: Open decompression (group A)
Number of subjects: 120
Study 7964196 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 30
Study 7964196 — intervention group
Group type: COMPARATOR
Intervention: Mobilization
Number of subjects: 30
Study 31463689 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 4.5‐mm cannulated partially threaded screws
Number of subjects: 9
Study 31463689 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture‐button construct
Number of subjects: 9
Study 29095000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (40% carbohydrates, 20% protein, 40% fats)
Number of subjects: 88
Study 29095000 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (50% carbohydrates, 20% protein, 30% fats)
Number of subjects: 88
Study 26450920 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib for 28 days followed by radical prostatectomy and pelvic lymph node dissection (RP/PLND)
Number of subjects: 46
Study 26450920 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy and pelvic lymph node dissection (RP/PLND) alone
Number of subjects: 46
Study 23312676 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-Omega3 (300mg PS-Omega3/day)
Number of subjects: 200
Study 23312676 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-Omega3 (150mg PS-Omega3/day) during open-label phase
Number of subjects: 200
Study 23312676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 21854596 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention (trained community outreach workers)
Number of subjects: 16
Study 21854596 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 16
Study 18334689 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly personal contact
Number of subjects: 1032
Study 18334689 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive technology‐based intervention
Number of subjects: 1032
Study 18334689 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed control
Number of subjects: 1032
Study 17142406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip core decompression followed by physical therapy
Number of subjects: 38
Study 17142406 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 38
Study 14563339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with abciximab (0.25mg/kg bolus and 0.125 microg/kg/min for 12h) and half‐dose reteplase (two boluses of 5U 30 min apart) with reduced‐dose heparin (60 Ukg(‐1) bolus, maximum 5000 U, followed by an infusion of 7 Ukg(‐1)h(‐1))
Number of subjects: 16588
Study 14563339 — intervention group
Group type: COMPARATOR
Intervention: Reteplase alone (10 U bolus twice, 30 min apart) with standard‐dose heparin (5000 U bolus followed by an infusion of 1000 Uh(‐1) for patients > or =80 kg and 800 Uh(‐1) for those <80 kg)
Number of subjects: 16588
Study 14563339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 16588
Study 14563339 — intervention group
Group type: COMPARATOR
Intervention: Reteplase alone
Number of subjects: 16588
Study 11056590 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 Immunogen administered intramuscularly every 12 weeks
Number of subjects: 2527
Study 11056590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (incomplete Freund adjuvant)
Number of subjects: 2527
Study 8752247 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nasogastric tube decompression
Number of subjects: 110
Study 8752247 — intervention group
Group type: COMPARATOR
Intervention: Intra-operative orogastric tube decompression
Number of subjects: 110
Study 1433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 532
Study 1433580 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 532
Study 4029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 0.5 g intravenous
Number of subjects: 36
Study 4029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 1 g intravenous
Number of subjects: 36
Study 4029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 2 g intravenous
Number of subjects: 36
Study 4029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 0.5 g intramuscular
Number of subjects: 36
Study 4029017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-reduction factors for temocillin
Number of subjects: 36
Study 31356125 — intervention group
Group type: EXPERIMENTAL
Intervention: Riding with an impaired driver (RWID)
Number of subjects: 668
Study 31356125 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving under the influence (DUI)
Number of subjects: 668